SCHEMBL624142

SCHEMBL624142

CC(C)COc1cc(N2CCN(C(=O)c3cc4ccccn4n3)CC2)ncn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.60
TSHR P16473 3/20 0.52
LMNA P02545 2/20 0.52
HSD17B10 Q99714 3/20 0.50
KDM4E B2RXH2 2/20 0.50
NPC1 O15118 1/20 0.50
HTT P42858 1/20 0.50
RAB9A P51151 1/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
MAPK1 P28482 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.46
HTR2A P28223 4/20 0.44
HTR2C P28335 2/20 0.44
HTR1A P08908 2/20 0.42
TP53 P04637 1/20 0.40
DRD2 P14416 4/20 0.39
DRD1 P21728 4/20 0.39
DRD4 P21917 4/20 0.39
DRD3 P35462 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623193 0.82 ALDH1A1 (0.61) ALDH1A1TSHRLMNAHSD17B10KDM4E
SCHEMBL624228 0.81 HTR2A (0.49) ALDH1A1TSHRNPC1RAB9AKMT2A
SCHEMBL624199 0.81 CYP1A2 (0.48) ALDH1A1KDM4EHPGD
SCHEMBL623165 0.80 CCKAR (0.44) ALDH1A1TSHRMEN1KMT2AHTR2A
SCHEMBL623189 0.79 PTK2 (0.51) TSHRMEN1KMT2AHTR1APOLB
SCHEMBL624496 0.79 TSHR (0.53) ALDH1A1TSHRKDM4ERAB9AMEN1
SCHEMBL623692 0.79 HRH4 (0.47) ALDH1A1TSHRLMNAHSD17B10KDM4E
SCHEMBL623267 0.79 KCNK3 (0.43) ALDH1A1TSHRHSD17B10KDM4EMEN1
SCHEMBL624384 0.79 MEN1 (0.34) ALDH1A1TSHRLMNAMEN1KMT2A
SCHEMBL623770 0.79 PSMB8 (0.38) ALDH1A1MEN1KMT2AHPGDCHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G ALDH1A1 2071/4885TSHR 1643/4885LMNA 2282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.